Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Lifecare AS ( (DE:LFC0) ) is now available.
Lifecare ASA has resubmitted its application to the Norwegian Medical Products Agency for authorization to begin its first-in-human clinical study of its proprietary Continuous Glucose Monitoring system. This resubmission follows feedback from the agency, which Lifecare has addressed to ensure compliance with regulatory standards. The study aims to confirm the safety and performance of the implantable sensor system and is a crucial step toward the company’s pivotal CE-marking study in 2026 and planned European commercial launch in 2027.
More about Lifecare AS
Lifecare ASA is a MedTech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management. The company focuses on using osmotic pressure as a sensing principle to monitor various body analytes, aiming to bring innovative CGM systems to market for both humans and pets.
YTD Price Performance: -28.16%
Average Trading Volume: 356,460
Current Market Cap: NOK167.7M
Learn more about LFC0 stock on TipRanks’ Stock Analysis page.